This was the stock's second consecutive day of losses.

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...

UnitedHealth reported fourth-quarter adjusted EPS of $6.81, up from $6.16 a year ago, beating the consensus of $6.72.

The stock's fall snapped a four-day winning streak.

Vertex stock today trades for about 24x forward earnings estimates. This is higher than in recent weeks but still very reasonable, considering Vertex's solid CF business and this new opportunity ...

Vertex stock trades at 23.8 times forward earnings (in line with the S&P 500), with $11.2 billion in cash and strong growth prospects. The healthcare sector has struggled to deliver worthwhile ...